The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Characterization of serum biomarkers for detection of early stage ovarian cancer
Abstract
We have previously reported the identification of three ovarian cancer biomarker panels comprised of SELDI‐TOF‐MS peaks representing 14 differentially expressed serum proteins for the diagnosis of ovarian cancer. Using micro‐LC‐MS/MS, we identified five m/z peaks as transthyretin (TTR 13.9 kDa, TTR fragment 12.9 kDa), beta‐hemoglobin (Hb, 15.9 kDa), apolipoprotein AI (ApoAI, 28 kDa) and transferrin (TF, 79 kDa). Western and/or ELISA methods confirmed the differential expression of TTR, Hb, and TF, and multivariate analyses resulted in improving the detection of early stage ovarian tumors (low malignant potential and malignant; receiver operating characteristic, ROC 0.933) as compared to cancer antigen CA125 alone (ROC 0.833). Interestingly, when CA125 was included with our markers in the multivariate analysis, the ROC increased to 0.959. Furthermore, multivariate analysis with only the mucinous subtype of early stage ovarian tumors, showed our markers to greatly improve the detection of disease (ROC 0.959) as compared to CA125 alone (ROC 0.613). Interestingly, the combination of CA125 with our markers did not seem to further improve the detection of mucinous tumors (ROC 0.955). We conclude that TTR, Hb, ApoAI and TF, when combined with CA125 should significantly improve the detection of early stage ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 934
Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J. A., & Reddy, S. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0334211100 · Cited by 638
Self-citationKozak, K. R., Amneus, M. W., Pusey, S. M., Su, F., Luong, M. N., Luong, S. A., Reddy, S. T., & Farias-Eisner, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2033602100 · Cited by 276
Self-citationRitchie, R. F., Palomaki, G. E., Neveux, L. M., Navolotskaia, O., Ledue, T. B., & Craig, W. Y. (1999) · Journal of Clinical Laboratory Analysis · doi:10.1002/(sici)1098-2825(1999)13:6<273::aid-jcla4>3.0.co;2-x · Cited by 270
Proteomic Approaches to Tumor Marker Discovery
Rai, A. J., Zhang, Z., Rosenzweig, J., Shih, I.-M., Pham, T., Fung, E. T., Sokoll, L. J., & Chan, D. W. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-1518-pattmd · Cited by 219
Cohen, L. S., Escobar, P. F., Scharm, C., Glimco, B., & Fishman, D. A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6253 · Cited by 203
Early Detection of Ovarian Cancer: Promise and Reality
Bast, R. C., Urban, N. D., Shridhar, V., Smith, D., Zhang, Z., Skates, S. J., Lu, K. H., Liu, J., Fishman, D. A., & Mills, G. B. (2002) · Cancer treatment and research · doi:10.1007/978-1-4757-3587-1_3 · Cited by 143
Cited by
Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J., Jackson, A. M., Hardie, D. B., Anderson, N. L., & Borchers, C. H. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800540-mcp200 · Cited by 515
Ovarian Cancer is Associated with Changes in Glycosylation in Both Acute-Phase Proteins and IgG
Saldova, R., Royle, L., Radcliffe, C. M., Abd Hamid, U. M., Evans, R., Arnold, J. N., Banks, R. E., Hutson, R., Harvey, D. J., Antrobus, R., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwm100 · Cited by 390
Handheld high-throughput plasmonic biosensor using computational on-chip imaging
Cetin, A. E., Coskun, A. F., Galarreta, B. C., Huang, M., Herman, D., Ozcan, A., & Altug, H. (2014) · Light: Science & Applications · doi:10.1038/lsa.2014.3 · Cited by 354
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome
Hortin, G. L. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.069252 · Cited by 351
Early Detection of Ovarian Cancer
Badgwell, D., & Bast, R. C. (2007) · Disease Markers · doi:10.1155/2007/309382 · Cited by 294
Metadata
- Authors
- Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., Reddy, S., & Farias‐Eisner, R.
- Venue
- PROTEOMICS
- Publisher
- Wiley
- Published
- 2005-11
- Volume
- 5
- Issue
- 17
- Pages
- 4589-4596
- ISSN
- 1615-9853 (ISSN-L)
- 1615-9861
- OpenAlex
- W2009368567
- Cited by
- 311
- References
- 17
- FWCI
- 25.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of serum biomarkers for detection of early stage ovarian cancer. https://app.cochat.ai/papers/10.1002/pmic.200500093
- The paper
- Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., Reddy, S., & Farias‐Eisner, R. (2005). Characterization of serum biomarkers for detection of early stage ovarian cancer. PROTEOMICS. https://doi.org/10.1002/pmic.200500093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.